



# AmeriHealth Caritas™

## District of Columbia

**To:** AmeriHealth Caritas DC Providers  
**Date:** March 17, 2022  
**Subject:** Discontinuation of Basaglar Exception

Dear Provider:

**Effective March 23, 2022, AmeriHealth Caritas District of Columbia (DC) will no longer permit Basaglar to pay at point of sale for enrollees.** Enrollees who have been receiving Basaglar due to a short-term supply issue with insulin glargine-yfgn will be required to switch back to one of our covered products now that the supply issues are resolved.

Please note that the current preferred long-acting insulins covered for AmeriHealth Caritas DC enrollees include the following products:

- **Semglee (insulin glargine)**
  - Semglee (insulin glargine) will pay at point of sale with a quantity limit of 30 milliliters per 30 days and is in the process of being phased out by the manufacturer.
- **Insulin glargine-yfgn**
  - Insulin glargine-yfgn will pay at point of sale with a quantity limit of 30 milliliters per 30 days.
  - It is considered interchangeable by the FDA, allowing substitution at pharmacies for the reference product, Lantus.
  - Information to order insulin glargine-yfgn:

Description	NDC Number	Strength	Pack size	WHOLESALE ORDER NUMBERS			
				Amerisource Bergen	Cardinal	McKesson	Morris & Dickson
Insulin Glargine (insulin glargine-yfgn) Multiple-Dose Vial <sup>LF</sup>	49502-393-80	100 units/mL (U-100)	1 Vial	10262946	5754783	2368157 2370781 CVS	141184
Insulin Glargine (insulin glargine-yfgn) Prefilled Pen <sup>LF</sup>	49502-394-75	100 units/mL (U-100)	5 pens	10263034	5754791	2368132 2370773 CVS	141168

If you have questions about this communication, please contact your Provider Account Executive or Provider Services at 202-408-2237.